Roche began shipping Axelios 1, its next-generation sequencing platform positioned as a challenge to Illumina’s dominance. The company is rolling out the system commercially with an initial focus on North America, Europe, and Asia-Pacific. The launch frames Roche’s strategy around accuracy, speed, flexibility, scalability, and cost efficiency—features intended to address practical bottlenecks in genomics workflows and give customers an additional scaling path for clinical and research sequencing.